БЛОГ

Oct 20, 2021

Anti-amyloid antibody receives Breakthrough Therapy Designation in US

Posted by in categories: biotech/medical, neuroscience

Roche’s gantenerumab is an anti-amyloid beta antibody developed for subcutaneous administration in Alzheimer’s disease patients.

Roche’s gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s disease (AD).

Comments are closed.